Hypothesis: Aprepitant plus ondansetron is more effective than ondansetron plus placebo for
prevention of postoperative emesis in patients at moderate-to-high risk for PONV for up to
48 hours after surgery.
Specific Aim: To determine the incidence of PONV during the first 48 hours after surgery; in
patients who have received aprepitant plus ondansetron versus ondansetron plus placebo for
up to 48 hours after surgery.
- Written informed consent
- ASA (American Society of Anesthesiologists physical status) 1-3
- Male and female Age 18 to 65 years
- Plastic surgical procedure (Breast, Face, Liposuction, etc., and excluding peripheral
procedures such as hand surgery and limited-scope split-thickness skin grafts) of at
least 1 hour in duration
- General anesthesia
- Presence of 2 (men)/3 (women) or more risk factors for PONV
- Ambulatory surgery with same-day discharge planned
- Patient refusal
- Patients who have received other antiemetics prior to their procedure
- History of allergy or sensitivity to study drugs
- Pregnancy - Patients are asked date of last menstrual period, use of birth control,
tubal ligation, if they have had unprotected sexual intercourse and if they think if
there is any possibility of being pregnant, and when appropriate, a pregnancy test
will be obtained which is the standard of care at Magee-Womens Hospital.
- Patients with a history of chronic opioid use (chronic pain syndrome) as these
patients will be less likely to have PONV